




RealRate

PHARMACEUTICAL 2014

PUMA Biotechnology INC
Rank 147 of 234



The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 65% points. The greatest weakness of PUMA Biotechnology INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 37% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	96,396
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,271
Liabilities, Non-Current	0
Other Assets	6,294
Other Compr. Net Income	3.0
Other Expenses	0
Other Liabilities	1,116
Other Net Income	196
Other Revenues	0
Property and Equipment	1,684
Research and Development	95,508
Selling, General and Administrative Expense	43,939

Output Variable	Value in 1000 USD
Assets	104,374
Liabilities	20,387
Expenses	139,447
Revenues	0
Stockholders Equity	83,987
Net Income	-139,251
Comprehensive Net Income	-139,250
BaseVar	132,204
ECR before LimitedLiability	70%
Economic Capital Ratio	206%